NASDAQConsumer StaplesTobaccoSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|---|---|
| Quarter ending 2026-12-30 | ||
| Revenue | — | 10.03M |
| EPS | — | -690 |
Management figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Secure $70M annual fee from Green Thumb starting April 2026 | The company targets a $70M annual fee from Green Thumb starting April 2026. | Intact | Annual fee from Green Thumb is less than $70M in FY2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. The fixed annual cash licensing fee of $70 million from Green Thumb took effect April 1, 2026, as confirmed in both Q1 and Q2 disclosures. This milestone is realized and stable, matching management's stated commitment. Delivery assessment Oct 24, 2026 |
Return to positive free cash flow | A supporting condition in RYTHM Inc's published investment case. The stated target is Free cash flow yield >= 0%. | Improving | Free cash flow yield remains negative over next 4 quarters | Valuation inputs unavailable A completed valuation measurement is required. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve $22M revenue in 2026-Q2 | A primary condition in RYTHM Inc's published investment case. The stated target is >= $22M revenue. | Intact | Revenue falls below $22M in 2026-Q2 | Revenue: $23.021M FY2026-Q2; GAAP. Published target: >= $22M revenue. The target does not explicitly identify fiscal versus calendar quarters. Source published Aug 4, 202623,021,000 USD · source valueSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f0c4a5d0-7d3d-4d8b-82fa-3fcca0cbe355. Source status: eligible. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 2 of last 2 quarters. Revenue grew from $13.3 million in 2026-Q1 to $23.0 million in 2026-Q2, exceeding the prior guidance of $22 million. Management has reiterated this revenue growth target and the trajectory is delivering with 73% sequential growth. Delivery assessment Oct 24, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 6, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business with a fragile earnings profile, not a steady compounder. Its thesis state is watch: recent performance is well below its industry cohort, while the evidence does not show a fresh break in the thesis.
RYM is described as cheap versus peers, and the available evidence indicates low priced-in fragility rather than a full combination of expensive valuation, weak execution, and turbulent conditions. The valuation model has medium confidence, and the snapshot does not specify which growth or earnings expectations the market assumes.
Near term, execution is mixed: second-quarter revenue reached $23.0 million against a stated $22 million priority, and hemp-derived product revenue grew 67% sequentially. The $70 million annual licensing fee from Green Thumb took effect, but recent financial performance remains weak, quality and management scores fell, and earnings misses are a meaningful risk. Over the multi-year view, growth depends on sustaining product expansion and the licensing arrangement while improving execution.
A guidance cut at the next call would be a meaningful negative, while continued weakening in jobs data could add pressure to cyclical businesses. Continued earnings strength and higher guidance from sector bellwethers such as PM, BTI, and MO would support the sector backdrop, but would not resolve RYM’s company-specific execution risks.
Over the next 1 to 3 years, RYM’s thesis balances encouraging revenue growth and a realized licensing fee against weak recent performance, declining quality indicators, and high risk. The key test is whether management can sustain growth and improve execution without cutting guidance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.